BLC
VRTX icon

Brown, Lisle/Cummings’s Vertex Pharmaceuticals VRTX Stock Holding History

Brown, Lisle/Cummings’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51.4K Buy
115
+33
+40% +$15.4K 0.01% 356
2025
Q4 		$37.2K Hold
82
– – 0.01% 369
2025
Q3 		$32.1K Hold
82
– – 0.01% 383
2025
Q2 		$36.5K Hold
82
– – 0.01% 367
2025
Q1 		$39.8K Buy
82
+7
+9% +$3.26K 0.01% 351
2024
Q4 		$30.2K Buy
+75
New +$34.8K 0.01% 370

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown, Lisle/Cummings's VRTX Position: Q1 2026 in Review

Brown, Lisle/Cummings increased its Vertex Pharmaceuticals (VRTX) stake by 40% in Q1 2026, buying an estimated $15.4K and bringing the position to 115 shares worth $51.4K. The position accounts for 0.01% of the portfolio, ranked #356.

Brown, Lisle/Cummings first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Brown, Lisle/Cummings held 115 shares of Vertex Pharmaceuticals worth $51.4K as of Q1 2026.
  • Brown, Lisle/Cummings bought 33 Vertex Pharmaceuticals shares in Q1 2026, an estimated $15.4K.
  • Vertex Pharmaceuticals made up 0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #356 holding.
  • Brown, Lisle/Cummings first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.